drugset / Trial / NCT00158405

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

NCT00158405

RandomizedParallel-groupOpen-labelTreatment

Summary

Interrupting HAART during limited periods of time ("structured treatment interruption : STI") could entail benefits (better long term tolerance, lower drug-induced viral resistance, lower cost) but also concomitant risks (lower efficacy, higher drug-induced viral resistance). At present, the benefit/risk ratio of STI is unclear. Several STI trials are in progress in industrialised countries. This trial aim at assessing the benefits and risks of two different STI strategies in West Africa.

Timeline

Start
2002-12
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified
Subject INDINAVIR ANHYDROUS Other / unclassified
Subject Lamivudine Other / unclassified
Subject Ritonavir Other / unclassified
Subject Zidovudine Small molecule